CN Bio raises $21 million USD in first close of Series B investment round

FHS
April 23, 2024
11:58 am

Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10 M and $5.5 M, respectively. Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions.

One-time prime editing targets common genetic cause of cystic fibrosis

Researchers optimized prime editing for the efficient correction of the cystic fibrosis transmembrane conductance regulator F508del mutation in human airway epithelial cells, achieving high correction

July 15, 2024

Life expectancy in India suffered large and unequal declines during COVID-19 pandemic

The international study, co-authored by the Department of Sociology and the Leverhulme Centre for Demographic Science’s Dr Aashish Gupta and Professor Ridhi Kashyap, reveals that

July 20, 2024

Avalo fails asthma PhII with lead candidate, shares crater

Avalo Therapeutics, a biotech working on immunology, said its lead candidate failed a Phase II study testing the treatment in a specific type of asthma

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.